<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562871</url>
  </required_header>
  <id_info>
    <org_study_id>IO102-012 / KN-764</org_study_id>
    <secondary_id>2018-000139-28</secondary_id>
    <secondary_id>KEYNOTE-764</secondary_id>
    <nct_id>NCT03562871</nct_id>
  </id_info>
  <brief_title>IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC</brief_title>
  <official_title>An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IO Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IO Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if IO102 combined with pembrolizumab with or
      without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung
      Carcinoma (NSCLC).

      The hypothesis is that IO102 will improve the objective response rate (ORR) in patients with
      metastatic NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 22, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 (safety run-in)</measure>
    <time_frame>One cycle i.e. 3 weeks</time_frame>
    <description>Dose Limiting Toxicity graded per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (efficacy)</measure>
    <time_frame>From date of randomization until date of death from any cause, withdrawal of consent or loss to follow up whichever came first, assessed for up to 35 cycles (2 years)</time_frame>
    <description>Objective Response Rate (ORR) evaluated by RECIST 1.1 and defined as the rate of complete response (CR) + partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>From date of randomization until date of death from any cause, withdrawal of consent or loss to follow up whichever came first, assessed for up to 35 cycles (2 years)</time_frame>
    <description>by baseline PD-L1 expression</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IO102</intervention_name>
    <description>test immunotherapy</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab (Keytruda)</intervention_name>
    <description>anti-PD-1 immunotherapy</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohort B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin (Carboplatin Kabi)</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohort B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed (Pemetrexed Alvogen)</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohort B2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic NSCLC or non squamous NSCLC

          -  Have biomarker-positive solid tumor

          -  Male participants of childbearing potential must agree to use an adequate method of
             contraception starting with the first dose of study medication through 120 days after
             the last dose of study medication

          -  Female participants of childbearing potential must be willing to use an adequate
             method of contraception for the course of the study through 120 days after the last
             dose of study medication

          -  The participant must provide written informed consent

          -  Have measurable disease per RECIST 1.1

          -  Have provided a blood sample and archival tumor tissue sample or newly obtained core
             or excisional biopsy of a tumor lesion not previously irradiated

          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent
             directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40,
             CD137) and was discontinued from that treatment due to a Grade 3 or higher
             immune-related AE (irAE)

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of treatment

          -  Radiotherapy within 2 weeks of start of trial treatment

          -  Vaccination with a live vaccine within 30 days prior to the first dose of trial
             treatment.Examples of live vaccines include, but are not limited to, the following:
             measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies,
             Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for
             injection are generally killed virus vaccines and are allowed; however, intranasal
             influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.

          -  Is currently participating in or has participated in a trial of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             trial treatment.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior the first dose of trial treatment.

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 2 years.

          -  Has known active CNS metastases and/or carcinomatous meningitis.

          -  Has severe hypersensitivity (≥Grade 3) to IO102, pembrolizumab, carboplatin,
             pemetrexed and/or any of its excipients.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years.

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Known active Hepatitis B or Hepatitis C

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the patient's
             participation for the full duration of the trial, or is not in the best interest of
             the patient to participate, in the opinion of the treating investigator.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperating with the requirements of the trial.

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Spicer, MD Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg gGmbH</name>
      <address>
        <city>Heidelberg</city>
        <state>Community Of Heidelberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PIUS Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stichting Het Nederlands Kanker Instituut</name>
      <address>
        <city>Amsterdam</city>
        <state>Community Of Amsterdam</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Oncología-El médico del Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <state>Andalusia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insituto Oncologico Dr Rosell. Hospital Universitario Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <state>Catalonia</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <state>Community Of Madrid</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <state>Community Of Madrid</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <state>Community Of Madrid</state>
        <zip>28134</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <state>Community Of Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de València</name>
      <address>
        <city>València</city>
        <state>Horta De València</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.</citation>
    <PMID>27745820</PMID>
  </reference>
  <reference>
    <citation>Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.</citation>
    <PMID>27718847</PMID>
  </reference>
  <reference>
    <citation>Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, Thor Straten P, Mellemgaard A, Andersen MH, Svane IM. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. Epub 2013 Nov 11.</citation>
    <PMID>24218513</PMID>
  </reference>
  <reference>
    <citation>Andersen MH. Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. J Natl Cancer Inst. 2015 Jun 10;107(9). pii: djv154. doi: 10.1093/jnci/djv154. Print 2015 Sep.</citation>
    <PMID>26063792</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Programmed Cell Death 1</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>IO102</keyword>
  <keyword>Keytruda</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All unpublished information relating to this trial and/or to the trial treatments is considered confidential by the Sponsor and shall remain the sole property of the Sponsor.
The Investigator must accept that the Sponsor may use the information from this clinical trial in connection with the development of the IO102, and therefore, may disclose it as required to other Investigators, to government licensing authorities, to regulatory agencies of other governments, stock exchange market, and commercial partners.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

